Table of Contents |
|||
|
Site Map |
Directory of CLL TopicsMajor CLL Topics Links |
||||
Backgound check on CLL Topics and its principals |
||||
Chaya Venkat's research and teaching credentials |
||||
The most recent additions, listed by date |
||||
A form to send us your input |
||||
Notes on a cord blood stem cell transplant |
||||
Guide to navigating the Topics website |
||||
Authoritative reference material available on the web |
||||
Search a variety of invaluable online databases |
||||
Reading material for a first-class online education |
||||
Subscribers can stay up to date on developments |
||||
Keep your records electronic, organized and handy |
||||
Alphabetic Subject Index | ||||
|
|
|||
An overview for the newly diagnosed |
||||
In tumor growth and as a therapy target |
||||
Newly available information |
||||
Standards of care in treating CLL and its complications |
||||
Its constituents and functions |
||||
Monoclonal antibody targeting the CD-52 antigen |
||||
To illustrate, demonstrate and educate |
||||
As they relate to cancer and especially CLL |
||||
Agents, therapies and consequences |
||||
Cycle of inflammation and CLL |
||||
Reviews and critical assessments of announced trials |
||||
Conditions that appear as CLL progresses |
||||
Expert reviews of the overall state of CLL Therapy |
||||
Clinical research sponsored and funded with your donations |
||||
Therapies involving cytotoxic T-cells |
||||
The natural history and typical features of CLL |
||||
Where some relevant questions and warnings are raised |
||||
The most active chemotherapy agent in CLL |
||||
A serial case history of a famous (hypothetical) patient |
||||
New generation human anti-CD20 monoclonal antibody |
||||
In sickness and in health |
||||
Reports from professional gatherings |
||||
General introduction and individual antibody reviews |
||||
Insight and commentary from patients |
||||
Insight and commentary from experts and practitioners |
||||
Chemoprevention: phytochemicals, nutrition and exercise |
||||
Key measurements to predict outcomes |
||||
Key first-generation anti-CD20 monoclonal antibody |
||||
Patient groups for information and assistance |
||||
Critical evaluation of clinical trial results and available protocols |
||||
Stem cell transplants: mortality vs. cure |
||||
Some promising new approaches |
||||
In CLL therapy, fighting infections and maintaining health |
||||
|
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———